Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers. Leveraging our novel MultiTAA technology – which uses non-genetically engineered T cells designed to recognize and kill multiple tumor targets – we believe we can develop more precise and safer therapies capable of resulting in broad, potent and durable anti-cancer activity. READ MORE
Data Provided by Refinitiv. Minimum 15 minutes delayed.